Literature DB >> 28824259

Unilateral Gynaecomastia in a Young Man with Chronic Myeloid Leukemia.

Ankur Jain1, Subhash Varma1, Rashi Garg2, Pankaj Malhotra1.   

Abstract

Male reproductive issues are frequently overlooked in patients of chronic myeloid leukemia (CML) on imatinib therapy. Current article describes a young man with CML on imatinib mesylate since 13 years who presented to us with painful left sided breast swelling. Mammography and fine needle aspiration cytology confirmed the diagnosis of gynaecomastia and hormone profile revealed low testosterone levels. Gynaecomastia was attributed to imatinib related hypogonadism. Gynaecomastia improved after hormone replacement therapy. Need for long term monitoring of reproductive hormones in patients of CML on imatinib therapy is emphasized in this report.

Entities:  

Keywords:  Chronic myeloid leukemia; Fine needle aspiration; Hypogonadism; Imatinib

Year:  2016        PMID: 28824259      PMCID: PMC5544650          DOI: 10.1007/s12288-016-0762-z

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  3 in total

Review 1.  The biology of signal transduction inhibition: basic science to novel therapies.

Authors:  J Griffin
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

2.  Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-alpha and -beta during human testicular development and disease.

Authors:  Sabrina Basciani; Stefania Mariani; Mario Arizzi; Salvatore Ulisse; Nadia Rucci; Emmanuele A Jannini; Carlo Della Rocca; Annamaria Manicone; Cesare Carani; Giovanni Spera; Lucio Gnessi
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

3.  Gynaecomastia in men with chronic myeloid leukaemia after imatinib.

Authors:  Carlo Gambacorti-Passerini; Lucia Tornaghi; Francesco Cavagnini; Pellegrino Rossi; Francesca Pecori-Giraldi; Luigi Mariani; Nadia Cambiaghi; Enrico Pogliani; Gianmarco Corneo; Lucio Gnessi
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.